Denali Therapeutics Inc.

20.75+0.9600+4.85%Vol 1.03M1Y Perf -36.24%
Oct 3rd, 2023 16:00 DELAYED
BID20.17 ASK21.28
Open19.62 Previous Close19.79
Pre-Market- After-Market21.48
 - -  0.73 3.52%
Target Price
60.92 
Analyst Rating
Strong Buy 1.29
Potential %
193.59 
Finscreener Ranking
★★★★     54.39
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.84
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     51.72
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
7.15 
Earnings Rating
Strong Buy
Market Cap2.85B 
Earnings Date
2nd Nov 2023
Alpha0.01 Standard Deviation0.18
Beta1.26 

Today's Price Range

19.5720.76

52W Range

19.6734.78

5 Year PE Ratio Range

-37.50136.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.48%
1 Month
-15.10%
3 Months
-33.32%
6 Months
-15.32%
1 Year
-36.24%
3 Years
-48.54%
5 Years
-6.65%
10 Years
-

TickerPriceChg.Chg.%
DNLI20.750.96004.85
AAPL172.40-1.3500-0.78
GOOG133.30-1.8700-1.38
MSFT313.39-8.4100-2.61
XOM115.830.20000.17
WFC38.67-0.9400-2.37
JNJ155.340.19000.12
FB196.640.99000.51
GE107.76-1.0300-0.95
JPM142.71-1.0600-0.74
Financial StrengthValueIndustryS&P 500US Markets
3.10
3.20
0.06
0.08
-
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-282.30
-274.80
-
8.38
RevenueValueIndustryS&P 500US Markets
98.18M
0.72
-1.45
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.861.30251.16
Q01 2023-0.71-0.80-12.68
Q04 2022-0.78-0.753.85
Q03 2022-0.83-0.84-1.20
Q02 2022-0.52-0.487.69
Q01 2022-0.47-0.53-12.77
Q04 2021-0.41-0.62-51.22
Q03 2021-0.51-0.69-35.29
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.837.78Positive
12/2023 QR-0.894.30Positive
12/2023 FY-1.2365.16Positive
12/2024 FY-3.168.41Positive
Next Report Date2nd Nov 2023
Estimated EPS Next Report-0.83
Estimates Count12
EPS Growth Next 5 Years %-
Volume Overview
Volume1.03M
Shares Outstanding137.42K
Shares Float106.23M
Trades Count13.89K
Dollar Volume20.86M
Avg. Volume737.47K
Avg. Weekly Volume824.48K
Avg. Monthly Volume793.96K
Avg. Quarterly Volume593.98K

Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 19.79 per share at the end of the most recent trading day (a -4.07% change compared to the prior day closing price) with a volume of 1.56M shares and market capitalization of 2.85B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.

The one-year performance of Denali Therapeutics Inc. stock is -36.24%, while year-to-date (YTD) performance is -28.84%. DNLI stock has a five-year performance of -6.65%. Its 52-week range is between 19.67 and 34.78, which gives DNLI stock a 52-week price range ratio of 7.15%

Denali Therapeutics Inc. currently has a PE ratio of -11.70, a price-to-book (PB) ratio of 4.84, a price-to-sale (PS) ratio of 38.50, a price to cashflow ratio of 10.60, a PEG ratio of -, a ROA of -24.64%, a ROC of -31.02% and a ROE of -36.26%. The company’s profit margin is 8.38%, its EBITDA margin is -274.80%, and its revenue ttm is $98.18 Million , which makes it $0.72 revenue per share.

Of the last four earnings reports from Denali Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.83 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.29), with a target price of $60.92, which is +193.59% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Denali Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.59, ATR14 : 0.86, CCI20 : -156.99, Chaikin Money Flow : -0.23, MACD : -1.01, Money Flow Index : 28.08, ROC : -18.12, RSI : 23.42, STOCH (14,3) : 2.44, STOCH RSI : 0.00, UO : 26.67, Williams %R : -97.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $136 200), Alexander O. Schuth (Sold 30 566 shares of value $856 489 ), Carole Ho (Sold 40 269 shares of value $1 115 668 ), Krognes Steve (Sold 6 466 shares of value $190 770 ), Marc Tessier-Lavigne (Sold 40 000 shares of value $1 215 063 ), Ryan J. Watts (Option Excercise at a value of $51 000), Ryan J. Watts (Sold 97 077 shares of value $2 759 474 ), SATO VICKI L (Sold 1 666 shares of value $49 709 ), Schuth Alexander (Sold 0 shares of value $-189 000 ), Schuth Alexander (Sold 51 191 shares of value $1 391 545 ), Steve E. Krognes (Sold 6 466 shares of value $190 770 ), Vicki L. Sato (Sold 3 332 shares of value $90 193 ), Watts Ryan (Sold 0 shares of value $-52 718 ), Watts Ryan (Sold 101 912 shares of value $2 874 860 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (85.71 %)
11 (84.62 %)
11 (84.62 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (14.29 %)
2 (15.38 %)
2 (15.38 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.31
Strong Buy
1.31

Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

CEO: Ryan J. Watts

Telephone: +1 650 866-8548

Address: 161 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 291

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

55%45%

Bearish Bullish

56%44%

 

TipRanks News for DNLI

Wed, 09 Aug 2023 11:58 GMT Denali Therapeutics price target lowered to $31 from $37 at Wedbush

- TipRanks. All rights reserved.

News

Stocktwits